Liquidia (LQDA) Non-Current Assets (2019 - 2026)
Liquidia's (LQDA) quarterly Non-Current Assets came in at $68.5 million in Q1 2026, up 36.35% year-on-year from $50.2 million in Q1 2025, and up 25.57% quarter-over-quarter from $54.5 million in Q4 2025.
Liquidia (LQDA) Non-Current Assets (2019 - 2026) Analysis & Trends
Liquidia's Non-Current Assets history runs 8 years deep, the most recent figure standing at $68.5 million for Q1 2026.
- On a quarterly basis, Non-Current Assets rose 36.35% year-over-year to $68.5 million in Q1 2026; TTM through Mar 2026 was $234.1 million, a 42.56% increase from a year earlier, with the FY2025 full-year figure at $54.5 million, up 20.63% from the prior year.
- Non-Current Assets advanced to $68.5 million in Q1 2026 per LQDA's latest filing, from $54.5 million in the prior quarter.
- Across five years, Non-Current Assets topped out at $68.5 million in Q1 2026 and bottomed at $28.4 million in Q4 2023.
- The 5-year median for Non-Current Assets is $30.6 million (2022), against an average of $39.0 million.
- Across the five-year window, Non-Current Assets slipped 10.08% in 2022 and surged 105.41% in 2025, its largest moves.
- Year by year, Non-Current Assets stood at $29.4 million in 2022, then dropped by 3.25% to $28.4 million in 2023, then soared by 59.0% to $45.2 million in 2024, then rose by 20.63% to $54.5 million in 2025, then advanced by 25.57% to $68.5 million in 2026.
- Per Business Quant, the three latest LQDA Non-Current Assets figures stand at $68.5 million (Q1 2026), $54.5 million (Q4 2025), and $49.3 million (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | 36.78 Bn |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | 26.33 Bn |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | 8.68 Bn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | 79.20 Bn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | 3.84 Bn |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | 15.70 Bn |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | 25.92 Bn |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | 2.47 Bn |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | 9.64 Bn |
| 10 | Liquidia | 7.84 Bn | 7.61 Bn | 121.79 Mn | 68.48 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 68.48 Mn |
| Dec 31, 2025 | 54.53 Mn |
| Sep 30, 2025 | 49.26 Mn |
| Jun 30, 2025 | 61.83 Mn |
| Mar 31, 2025 | 50.22 Mn |
| Dec 31, 2024 | 45.21 Mn |
| Sep 30, 2024 | 38.67 Mn |
| Jun 30, 2024 | 30.10 Mn |
| Mar 31, 2024 | 29.18 Mn |
| Dec 31, 2023 | 28.43 Mn |
| Sep 30, 2023 | 28.66 Mn |
| Jun 30, 2023 | 28.71 Mn |
| Mar 31, 2023 | 29.23 Mn |
| Dec 31, 2022 | 29.39 Mn |
| Sep 30, 2022 | 29.51 Mn |
| Jun 30, 2022 | 30.58 Mn |
| Mar 31, 2022 | 31.57 Mn |
| Dec 31, 2021 | 32.45 Mn |
| Sep 30, 2021 | 32.82 Mn |
| Jun 30, 2021 | 33.06 Mn |